RxDoctor Payments DataLook up a doctor →

Ravinder Bhalla, MD

Child & Adolescent Psychiatry · Ridgewood, NJNPI 1841214566

Payments from drug & device makers

$125,032in general payments, 2019–2025

Across 884 payments — averaging $141.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$88K
  • AbbVie$15K
  • Alkermes, Inc.$12K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Lundbeck LLC$1K
  • plus $4K from 20 others

What the payments were for

  • Consulting fees$6,5005%
  • Speaking & faculty fees$100,82581%
  • Travel & lodging$1,7411%
  • Food & beverage$15,63513%
  • Education$3310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,032 in reported general payments places this provider in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.

See all child & adolescent psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$82,365
Medicare patients
107
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine15$111,550
IngrezzaValbenazine Tosylate11$86,655
AristadaAripiprazole Lauroxil21$69,837
Abilify MaintenaAripiprazole13$38,404
FanaptIloperidone13$26,779
Invega SustennaPaliperidone Palmitate13$22,791
Lurasidone Hcl25$15,745
Divalproex Sodium ErDivalproex Sodium80$2,122
Quetiapine Fumarate81$1,339
Lamotrigine61$648
Aripiprazole27$567
Doxepin Hcl47$417
Risperidone47$417
Quetiapine Fumarate ErQuetiapine Fumarate17$411
Buspirone Hcl12$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$88,445$111,55015 claims
Neurocrine Biosciences, Inc.Ingrezza$1,124$86,65511 claims
Alkermes, Inc.Aristada$11,598$69,83721 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,267$38,40413 claims
Vanda Pharmaceuticals Inc.Fanapt$375$26,77913 claims
Johnson & JohnsonInvega Sustenna$699$22,79113 claims
Almatica Pharma LLCSertraline Hcl$13$8029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.

Other child & adolescent psychiatry in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →